There’s no approved medication to treat patients with epilepsy so severe that they must be put into a coma to stop their seizures. An experimental drug from Sage Therapeutics (SAGE) (SAGE) aims to fill that void — if the key phase 3 clinical trial yields positive results. It’s expected to read out results within the next month.
It’ll be a pivotal moment not just for the patients, but for Sage and its investors. Here are seven things to know about Sage, which is based in Cambridge, Mass., and its epilepsy drug, brexanolone: